Physician profile
Dean C Dimmitt
NPI 1447334800
$3,731.64
in general payments reported to CMS, 2019-2025
34 companies · $926 in 2025
The $926 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $172 · 2021: $581 · 2022: $339 · 2023: $161 · 2024: $736 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $456.69 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $301.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $251.91 | 2019-2021 | |
| Abbvie INC. | $248.37 | 2019-2024 | Qulipta |
| Sumitomo Pharma America, INC. | $238.50 | 2024-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $229.52 | 2019-2023 | Eliquis, Camzyos |
| Pfizer INC. | $229.09 | 2019-2025 | |
| Amgen INC. | $216.72 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $183.51 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $177.26 | 2019-2023 | Veozah |
| Cleerly, INC. | $148.20 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Sanofi-Aventis U.S. LLC | $144.40 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.28 | 2024-2025 | Ofev, Jascayd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.64 | 2025 | |
| Janssen Pharmaceuticals, INC | $67.35 | 2019-2021 | |
| Teleflex LLC | $49.53 | 2023 | Urolift |
| Eisai INC. | $47.74 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $44.64 | 2019-2020 | |
| Gilead Sciences, INC. | $42.80 | 2025 | |
| Itamar Medical INC | $41.58 | 2022-2024 | Watchpatone |
| Teva Pharmaceuticals USA, INC. | $27.72 | 2019-2020 | |
| Allergan, INC. | $25.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.19 | 2019 | |
| Medtronic, INC. | $24.10 | 2025 | Symplicity G3 |
| Verity Pharmaceuticals INC. | $18.26 | 2025 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $15.64 | 2021 | |
| Lilly USA, LLC | $14.58 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.25 | 2019 | |
| Ge Healthcare | $14.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2019 | |
| Merck Sharp & Dohme LLC | $13.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Dimmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.